Molecular assay-analyzer

Ended Purchase Order Awarded Last action

Contract number
N6264520P0020
Awardee
Awarding agency
Obligated
$3,135,166

Award facts

Opportunity
Contract value 100% obligated
$3,135,166.44 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Contracting staff
Set-aside
No set-aside
Competition
Not Competed under SAP · 1 offer Simplified Acquisition
Pricing
Firm Fixed Price
Place of performance
Emigration Canyon, UT 84108, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Funding Only Action P00016 -$438,886
Other Administrative Action P00015 $0
Funding Only Action P00014 -$47,847
Supplemental Agreement for work within scope P00013 · Molecular assay-analyzer for naval hospital camp pendleton -$2,558,107
Other Administrative Action P00012 $1,143,112
Exercise an Option P00011 $0
Exercise an Option P00010 $1,143,112
Supplemental Agreement for work within scope P00009 -$66,675
Exercise an Option P00008 $1,209,787
Other Administrative Action P00007 · The subject award is being transferred to the new issuing office (HT9406) at a new agency - DHA. $0
Supplemental Agreement for work within scope P00006 -$53,187
Supplemental Agreement for work within scope P00005 $0
Exercise an Option P00004 $1,262,974
Supplemental Agreement for work within scope P00003 $239,236
Supplemental Agreement for work within scope P00002 $19,603
Supplemental Agreement for work within scope P00001 $536,016
Original award $746,027
Show all 17

About this award

Written by GovTribe AI ·

The Defense Health Agency awarded a $3.14 million firm fixed-price purchase order to Biofire Diagnostics LLC for a molecular assay-analyzer system to support the Naval Medical Center Portsmouth, Virginia. The contract, which was awarded on April 16, 2020, with an ultimate completion date of April 15, 2025, provides laboratory analyzer equipment, associated reagents, maintenance, and consumables capable of performing syndromic infectious disease testing. The analyzer must test for respiratory, blood culture, gastrointestinal, and meningitis/encephalitis targets, including COVID-19 detection capabilities, and will operate on a walkaway platform to process specified minimum yearly testing volumes. The award includes installation and training services upon delivery at the contractor's place of performance in Emigration Canyon, Utah.

This purchase order was issued without a set-aside designation, reflecting Biofire Diagnostics' competitive standing in the federal marketplace. Biofire Diagnostics is a Salt Lake City–based biotechnology company specializing in advanced molecular diagnostic testing solutions, with an established portfolio of federal contracts primarily serving the Department of Veterans Affairs, Indian Health Service, Defense Health Agency, and Department of State. The company's FilmArray diagnostic systems and associated reagent panels have become a cornerstone of federal healthcare diagnostic capabilities, with multiple long-term blanket purchase agreements and indefinite delivery vehicles in place across various federal healthcare systems valued in the millions of dollars and spanning performance periods through 2027.

Quick answers

Who was awarded contract N6264520P0020?

N6264520P0020 was awarded to Biofire Diagnostics LLC by Defense Health Agency (Department of Defense) on April 16, 2020.

How much is contract N6264520P0020 worth?

The government has obligated $3,135,166 on N6264520P0020.

Was contract N6264520P0020 competed?

The extent of competition for N6264520P0020 was not competed under sap. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login